摘要
目的评价国产比阿培南治疗支气管扩张症合并细菌感染的疗效和安全性。方法将支气管扩张症合并细菌感染患者98例随机分为两组,比阿培南组(n=48)静脉滴注比阿培南,300~600 mg/次,2次/d;对照组(n=50)静脉滴注美罗培南,500~1 000 mg/次,3次/d,疗程均为7~10 d。结果比阿培南组与对照组治疗支气管扩张症合并细菌感染的临床有效率分别为89.58%(43/48)8、4.00%(42/50);细菌清除率分别为92.86%(26/28)、88.24%(30/34),不良反应发生率分别为6.25%(3/48)、10.00%(5/50),两组比较,差异均无统计学意义(P>0.05)。结论国产比阿培南可安全、有效地治疗支气管扩张症合并细菌感染。
Objective To evaluate the clinical effectiveness and safety of domestic biapenem in the treatment of bronchiectasis complicated with bacterial infections.Methods Ninety-eight patients with bronchiectasis complicated with bacterial infections were randomly divided into two groups:Biapenem group(n=48) which biapenem was administered by intravenous drip infusion at a dose of 300-600 mg twice a day;Control group(n=50) which meropenem was administered by intravenous drip infusion at a dose of 500-1 000 mg three times a day.Their course of treatment both were 7-10 days.Results The clinical effective rate of the biapenem group and the control group were 89.58%(43/48) and 84.00%(42/50),respectively;bacterial eradication rate of them were 92.86%(26/28) and 88.24%(30/34),respectively,and the incidence rates of adverse reactions were 6.25%(3/48) and 10.00%(5/50),respectively.There was no significant difference between two groups(P0.05).Conclusion It is effective and safe to treat bronchiectasis complicated with bacterial infections using domestic biapenem.
出处
《重庆医学》
CAS
CSCD
北大核心
2011年第16期1585-1587,共3页
Chongqing medicine
关键词
抗感染药
支气管扩张症
细菌感染
比阿培南
anti-infective agents
bronchiectasis
bacterial infections
biapenem
meropenem